Comparative Pharmacology
Head-to-head clinical analysis: LIDOCAINE HYDROCHLORIDE VISCOUS versus ROPIVACAINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LIDOCAINE HYDROCHLORIDE VISCOUS versus ROPIVACAINE HYDROCHLORIDE.
LIDOCAINE HYDROCHLORIDE VISCOUS vs ROPIVACAINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lidocaine is a local anesthetic that stabilizes neuronal membranes by blocking voltage-gated sodium channels, thereby inhibiting the initiation and propagation of action potentials. It also has antiarrhythmic properties (Class Ib) by accelerating repolarization and reducing automaticity in cardiac tissues.
Ropivacaine is an amide-type local anesthetic that reversibly blocks nerve impulse propagation by inhibiting sodium ion influx via voltage-gated sodium channels in neuronal cell membranes.
Adult: 15 mL (300 mg) orally every 3 hours, not to exceed 8 doses in 24 hours. Viscous formulation swished and swallowed.
0.2% to 0.5% solution; epidural: 15-30 mg bolus, then 6-14 mg/hour infusion; peripheral nerve block: 0.5% solution, 20-30 mL; local infiltration: 0.2% solution, up to 200 mg total.
None Documented
None Documented
Terminal elimination half-life: 1.5–2 hours (adults); prolonged in heart failure (2.5–4 hours) or hepatic disease (up to 5–7 hours). Context: short t1/2 limits toxic accumulation with topical use.
Terminal elimination half-life: 1.8–2.7 hours (mean 2.0 h) in adults. In neonates, prolonged to 3–6 hours due to immature hepatic clearance.
Renal: ~90% as metabolites (mainly 4-hydroxy-2,6-xylidine and glucuronides), <10% unchanged. Biliary/fecal: minor (<5%).
Renal: 86% as metabolites and unchanged drug (primarily 3-hydroxy-ropivacaine and 4-hydroxy-ropivacaine glucuronides). Fecal: <1%. Biliary: minor.
Category A/B
Category A/B
Local Anesthetic / Antiarrhythmic (Class Ib)
Local Anesthetic